Overview Treatment of Familiar Lymphohistiocytosis Status: Completed Trial end date: 2020-05-20 Target enrollment: Participant gender: Summary The purpose of this project is to study the number of surviving patients until hematopoietic stem cell transplantation (HSCT) after first line treatment of hemophagocytic lymphohistiocytosis (HLH) by Alemtuzumab Phase: Phase 1/Phase 2 Details Lead Sponsor: Assistance Publique - Hôpitaux de ParisTreatments: AlemtuzumabCyclosporineCyclosporinsMethylprednisoloneMethylprednisolone AcetateMethylprednisolone HemisuccinatePrednisolonePrednisolone acetatePrednisolone hemisuccinatePrednisolone phosphate